Rugeles M T, Aitouche A, Zeevi A, Fung J J, Watkins S C, Starzl T E, Rao A S
Thomas E. Starzl Transplantation Institute and the Department of Surgery, University of Pittsburgh Medical Center, Pennsylvania 15261, USA.
Transplantation. 1997 Sep 15;64(5):735-41. doi: 10.1097/00007890-199709150-00013.
We have postulated that the donor leukocyte microchimerism plays a seminal role in the acceptance of allografts by inducing and perpetuating variable degree of donor-specific nonreactivity in long-surviving organ recipients. Limited information is available, however, concerning the phenotype and function of these chimeric cells in humans. The unequivocal presence of donor dendritic cells (DCs), a prominent lineage in the microchimerism observed in rodents and clinical organ recipients, was difficult to demonstrate in bone marrow (BM)-augmented organ transplant recipients. This enigma was resolved by the recent description of a method for propagating circulating human DCs from their progenitors by culture in a medium enriched with granulocyte-macrophage colony-stimulating factor and interleukin 4, a condition known to inhibit outgrowth of monocytes, thus providing a selective growth advantage to committed progenitors of the myeloid lineage. Cells from BM-augmented organ recipients and normal control subjects harvested from 12- to 14-day cultures exhibited dendritic morphology and potent allostimulatory capacity. Using appropriate primers, the presence of donor DNA was verified by polymerase chain reaction within the lineage(null)/class II(bright) sorted DC. Phenotypic analysis of cultured DCs from BM-augmented patients, unlike that of controls, exhibited a marked down-regulation of B7-1 (CD80) while retaining normal levels of expression of B7-2 (CD86) cell surface molecules. The presence of donor DNA was also confirmed by polymerase chain reaction in individually sorted lineage+ (T, B, and NK) cells and macrophages, suggesting that the chimerism in BM-augmented patients is multilineage. The presence of progenitors of donor DCs in the peripheral blood of BM-augmented patients further substantiates the already convincing evidence of stem cell engraftment.
我们推测,供体白细胞微嵌合体通过诱导并维持长期存活的器官受者体内不同程度的供体特异性无反应性,在同种异体移植物的接受过程中发挥着关键作用。然而,关于这些嵌合细胞在人类中的表型和功能,目前所知甚少。在骨髓增强器官移植受者中,很难明确证实供体树突状细胞(DCs)的存在,而在啮齿动物和临床器官受者中观察到的微嵌合体中,DCs是一个突出的谱系。最近描述了一种方法,可通过在富含粒细胞-巨噬细胞集落刺激因子和白细胞介素4的培养基中培养,从其祖细胞中扩增循环中的人DCs,这种条件已知可抑制单核细胞的生长,从而为髓系谱系的定向祖细胞提供选择性生长优势,这一谜团因此得以解决。从12至14天培养物中收获的骨髓增强器官移植受者和正常对照受试者的细胞呈现出树突状形态,并具有强大的同种异体刺激能力。使用适当的引物,通过聚合酶链反应在谱系(null)/II类(明亮)分选的DC内验证了供体DNA的存在。与对照组不同,对骨髓增强患者培养的DCs进行表型分析时,发现B7-1(CD80)显著下调,而B7-2(CD86)细胞表面分子的表达水平保持正常。通过聚合酶链反应在单独分选的谱系+(T、B和NK)细胞和巨噬细胞中也证实了供体DNA的存在,这表明骨髓增强患者中的嵌合体是多谱系的。骨髓增强患者外周血中存在供体DC的祖细胞,这进一步证实了干细胞植入这一已有充分说服力的证据。